| Pembrolizumab for early triple-negative breast cancer P Schmid, J Cortes, L Pusztai, H McArthur, S Kümmel, J Bergh, C Denkert, ... New England Journal of Medicine 382 (9), 810-821, 2020 | 2469 | 2020 |
| Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study S Adams, S Loi, D Toppmeyer, DW Cescon, M De Laurentiis, R Nanda, ... Annals of Oncology 30 (3), 405-411, 2019 | 609 | 2019 |
| KEYNOTE-522: Phase III study of pembrolizumab (pembro)+ chemotherapy (chemo) vs placebo (pbo)+ chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment … P Schmid, J Cortés, R Dent, L Pusztai, HL McArthur, S Kuemmel, J Bergh, ... Annals of Oncology 30, v853-v854, 2019 | 106* | 2019 |
| LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo)+ chemotherapy (chemo), followed by adjuvant pembro or pbo+ endocrine therapy (ET) for … F Cardoso, HL McArthur, P Schmid, J Cortés, N Harbeck, ML Telli, ... Annals of Oncology 34, S1260-S1261, 2023 | 95 | 2023 |
| Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048 D Rischin, KJ Harrington, R Greil, D Soulieres, M Tahara, G de Castro Jr, ... Oral oncology 128, 105815, 2022 | 26 | 2022 |
| KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early … F Cardoso, A Bardia, F Andre, DW Cescon, HL McArthur, ML Telli, S Loi, ... Journal of Clinical Oncology 37 (15_suppl), TPS601-TPS601, 2019 | 25 | 2019 |
| Pembrolizumab plus chemotherapy followed by pembrolizumab in patients with early triple-negative breast cancer: a secondary analysis of a randomized clinical trial M Takahashi, J Cortés, R Dent, L Pusztai, H McArthur, S Kümmel, ... JAMA network open 6 (11), e2342107-e2342107, 2023 | 24 | 2023 |
| KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage … F Cardoso, A Bardia, F André, DW Cescon, H McArthur, M Telli, S Loi, ... Annals of Oncology 30, ix7-ix8, 2019 | 14* | 2019 |
| 135MO HRQoL with neoadjuvant pembrolizumab+ chemotherapy vs placebo+ chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522 RA Dent, J Cortés, L Pusztai, HL McArthur, S Kuemmel, J Bergh, ... Annals of Oncology 33, S600-S601, 2022 | 8 | 2022 |
| Abstract GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage … F Cardoso, J O'Shaughnessy, H McArthur, P Schmid, J Cortés, N Harbeck, ... Cancer Research 84 (9_Supplement), GS01-02-GS01-02, 2024 | 7 | 2024 |
| Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study R Dent, J Cortés, L Pusztai, H McArthur, S Kümmel, J Bergh, C Denkert, ... JNCI: Journal of the National Cancer Institute 116 (10), 1654-1663, 2024 | 5 | 2024 |
| KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or … HS Rugo, J Sohn, Y Jerez Gilarranz, L Gonzalez-Cortijo, A Sonnenblick, ... Journal of Clinical Oncology 40 (16_suppl), TPS1118-TPS1118, 2022 | 5 | 2022 |
| 1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo)+ chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple … R Dent, J Cortes, L Pusztai, HL McArthur, S Kuemmel, J Bergh, C Denkert, ... Annals of Oncology 31, S1241-S1242, 2020 | 5 | 2020 |
| Estimating the Pólya process Y Feng, X Chen, L Jia, X Song, HM Mahmoud Communications in Statistics-Theory and Methods 46 (19), 9397-9406, 2017 | 3 | 2017 |
| Neoadjuvant pembrolizumab or placebo+ chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2–breast cancer … F Cardoso, J O’Shaughnessy, H McArthur, P Schmid, J Cortes, N Harbeck, ... European Journal of Cancer 200, 2024 | 2 | 2024 |
| KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high … F Cardoso, A Bardia, F Andre, DW Cescon, H McArthur, M Telli, S Loi, ... CANCER RESEARCH 79 (4), 2019 | 2* | 2019 |
| 433TiP Phase III, randomized, open-label TroFuse-010 Study of sacituzumab tirumotecan (sac-TMT) alone and with pembrolizumab vs treatment of physician’s choice chemotherapy … SM Tolaney, P D’Amico, L Jia, KM Hirshfield, F Cardoso Annals of Oncology 35, S402, 2024 | 1 | 2024 |
| Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial F Cardoso, J O’Shaughnessy, Z Liu, H McArthur, P Schmid, J Cortes, ... Nature Medicine, 1-7, 2025 | | 2025 |
| Neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for earlystage high-risk ER+/HER2-breast cancer … F Cardoso, J O'Shaughnessy, H McArthur, P Schmid, J Cortes, N Harbeck, ... EUROPEAN JOURNAL OF CANCER 200, 10-11, 2024 | | 2024 |
| PS2-3 Neoadjuvant pembrolizumab/placebo+ chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup M Takahashi, J Cortes, R Dent, L Pusztai, H Mcarthur, S Kuemmel, ... Annals of Oncology 33, S465, 2022 | | 2022 |
